These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 13680379)

  • 21. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
    Nishimoto A; Yu Y; Lu Z; Mao X; Ren Z; Watowich SS; Mills GB; Liao WS; Chen X; Bast RC; Luo RZ
    Cancer Res; 2005 Aug; 65(15):6701-10. PubMed ID: 16061651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
    Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor--mediated stat3 signaling blocks apoptosis in head and neck cancer.
    Rubin Grandis J; Zeng Q; Drenning SD
    Laryngoscope; 2000 May; 110(5 Pt 1):868-74. PubMed ID: 10807365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Yes-associated Protein with Evolved Peptide Aptamers to Disrupt TGF-β Signaling Pathway: Therapeutic Implication for Bone Tumor.
    Ji WP; Dong Y
    Mol Inform; 2015 Nov; 34(11-12):771-7. PubMed ID: 27491038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
    Bellail AC; Hao C
    Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
    [No Abstract]   [Full Text] [Related]  

  • 26. Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP.
    Cui Q; Lim SK; Zhao B; Hoffmann FM
    Oncogene; 2005 Jun; 24(24):3864-74. PubMed ID: 15750622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Association for Cancer Research--94th Annual Meeting. New compounds. 11-14 July 2003, Washington, DC, USA.
    Mackay J; Williams L
    IDrugs; 2003 Aug; 6(8):733-5. PubMed ID: 12971387
    [No Abstract]   [Full Text] [Related]  

  • 28. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach.
    French JD; Tschumper RC; Jelinek DF
    Leukemia; 2002 Jun; 16(6):1189-96. PubMed ID: 12040452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
    Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
    Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.
    Xi S; Gooding WE; Grandis JR
    Oncogene; 2005 Feb; 24(6):970-9. PubMed ID: 15592503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
    Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
    Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L; Turkson J; Karras JG; Jove R; Haura EB
    Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
    Buettner R; Mora LB; Jove R
    Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
    Chang C; Takayanagi A; Yoshida T; Shimizu N
    Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
    Tuck AB; Hota C; Wilson SM; Chambers AF
    Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.
    Real PJ; Sierra A; De Juan A; Segovia JC; Lopez-Vega JM; Fernandez-Luna JL
    Oncogene; 2002 Oct; 21(50):7611-8. PubMed ID: 12400004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIFing the brakes: therapeutic opportunities for treatment of human malignancies.
    Garcia JA
    Sci STKE; 2006 May; 2006(337):pe25. PubMed ID: 16738063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).
    Hambek M; Baghi M; Baumaun H; Strebhardt K; Adunka O; Gstöttner W; Knecht R
    Anticancer Res; 2005; 25(3B):1871-5. PubMed ID: 16158919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.